Added to YB: 2026-06-10
Pitch date: 2026-06-08
SHILPAMED.NS [neutral]
Shilpa Medicare Limited
Author Info
Abhay is identifying high conviction ideas & providing insights on thematic investing. Sign up for the newsletter.
Company Info
Shilpa Medicare Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, biosimilars, and contract development and manufacturing organisation in India, the United States, Europe, and internationally.
Market Cap
INR 104.2B
Pitch Price
N/A
Price Target
N/A
Dividend
0.11%
EV/EBITDA
24.42
P/E
42.83
EV/Sales
7.17
Sector
Pharmaceuticals
Category
growth
Shilpa Medicare Limited - $SHILPAMED.NS
SHILPAMED.NS (overview): Indian vertically-integrated pharma pivoting from oncology APIs to complex generics, biosimilars, ADCs & CDMO. Catalysts: Unicycive OLC PDUFA Jun 29 2026, Rotigotine patch EU launch, NorUDCA NAFLD drug, Aflibercept/Nivolumab biosimilars, Orion albumin deal. Risks: USFDA inspections, OLC client concentration, heavy R&D capex (₹361cr FY26), lumpy licensing income, ₹613cr net debt.
Read full article (11 min)